Risk scores in patients with acute coronary syndromes

Original title: Walking Beyond the GRACE (Global Registry of Acute Coronary Events) Model in the Death Risk Stratification During Hospitalization in Patients With Acute Coronary Syndrome. Reference: Rapouseiras-Roubín S, et al. J Am Coll Cardiol Intv 2012;5:1117–25.

Discriminatory power of risk score predictors become fundamental in the management of patients with acute coronary syndromes. This tool lets you define, for example, which patients will benefit most from more aggressive strategies such as early percutaneous revascularization.

Accordingly, several risk scores have been proposed. One of the most widely used in medical practice, the GRACE score, was drafted in 2003 and rapidly became popular owing to its wide applicability. Another widely used score is the one we set in this context; ACTION.

The aim of this study in a single center in Spain was to compare the predictive ability of traditional risk scores, (GRACE and ACTION), with more contemporary scores, (EHS and NCDR). 4,497 consecutive patients were included, of whom 32.1% had MI with ST-segment elevation. Traditional scores from the predictors GRACE and ACTION showed an excellent performance in predicting. Additionally, the more recent prediction scores from NCDR and EHS were not superior to the traditional in this context.

Conclusion 

The GRACE score remains a tool with great clinical applicability for the prediction of adverse cardiovascular events in patients with acute coronary syndromes.

Editorial Comment:

The major limitation of the study lies in the fact it came from a single center whose inclusion of patients was performed consecutively. However, the significant number of patients included allows generalizing the conclusion (external validity) that the GRACE score remains one of the most useful tools for predicting cardiovascular risk in patients with acute coronary syndromes.

Courtesy of Dr. Marco Wainstein
Editorial Board Member

Dr. Marco Wainstein

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...